Rationally designed Mycoplasma gallisepticum vaccine using a recombinant subunit approach

Area of Science:

• Veterinary immunology
• Avian pathology
• Vaccine development

Background:

• Mycoplasma gallisepticum (MG) causes significant economic losses in poultry due to respiratory disease.
• Existing vaccines have limitations in efficacy, utility, and safety.

Purpose of the Study:

• To develop and evaluate a novel subunit vaccine against Mycoplasma gallisepticum.
• To identify an effective adjuvant formulation for the subunit vaccine.

Main Methods:

• A subunit vaccine was formulated with recombinant MG proteins: GapA, CrmA, and VlhAs (3.03, 3.06, 4.07, 5.05).
• Chickens received a prime-boost vaccination with 50 µg/protein via subcutaneous injection.
• Vaccine efficacy was assessed against virulent MG strain Rlow challenge, comparing different adjuvant formulations.

Main Results:

• The subunit vaccine formulation with CpG oligodeoxynucleotide (CpG ODN 2007) significantly reduced MG recovery in chickens.
• This adjuvant formulation also led to significant reductions in tracheal pathology.
• Other adjuvants tested showed variable protection levels.

Conclusions:

• A rationally designed subunit vaccine is effective against Mycoplasma gallisepticum.
• The combination of the subunit vaccine with CpG ODN 2007 provides a safe and efficacious strategy against MG disease.